Barclays initiated coverage of Celldex Therapeutics, Inc. (NASDAQ:CLDX) with an Underweight rating, citing potential risks despite promising clinical data. The company focuses on developing innovative therapies for various diseases.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing